ITOS Oct 2024 11.000 call
| Previous close | 2.2000 |
| Open | 2.2000 |
| Bid | 6.6000 |
| Ask | 10.1000 |
| Strike | 11.00 |
| Expiry date | 2024-10-18 |
| Day's range | 2.2000 - 2.2000 |
| Contract range | N/A |
| Volume | |
| Open interest | 63 |
Simply Wall St.Should Shareholders Reconsider iTeos Therapeutics, Inc.'s (NASDAQ:ITOS) CEO Compensation Package?
Key Insights iTeos Therapeutics will host its Annual General Meeting on 11th of June Salary of US$578.9k is part of CEO...
GlobeNewswireiTeos Reports First Quarter 2024 Financial Results and Provides Business Updates
- Belrestotug + dostarlimab exceeded pre-defined efficacy criteria for clinically relevant activity observed in an interim assessment of Phase 2 GALAXIES Lung-201- Clinically meaningful tumor reduction observed at every belrestotug + dostarlimab dose vs monotherapy- GSK to provide update on GALAXIES program at upcoming investor event in June- RA Capital and Boxer Capital led $120 million registered direct offering at $17.50, representing a premium of approximately 44% to last close- Pro forma ca
- GlobeNewswire
iTeos Therapeutics Announces $120 Million Registered Direct Offering
- Led by existing investors RA Capital Management and Boxer Capital- Purchase price of $17.50 represents a premium of approximately 44% to last close- Further strengthens balance sheet with pro forma cash position of $715 million, extending anticipated runway through 2027 WATERTOWN, Mass. and GOSSELIES, Belgium, May 10, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) (“iTeos”), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generatio
